Press releases
2023
12 September, 2023
Egetis to participate at medical conferences to increase disease awareness about MCT8 deficiency
30 August, 2023
Egetis to participate at upcoming investor conferences
22 August, 2023
Interim report Q2 2023
24 July, 2023
Egetis announces first patient included and second site activated in the pivotal ReTRIACt trial
28 June, 2023
Egetis announces site activation in the pivotal ReTRIACt trial for Emcitate® and updates timeline for the US NDA submission
16 June, 2023
Board directors in Egetis Therapeutics acquire shares
26 April, 2023
Interim report January-March 2023
30 March, 2023
Egetis comments on market rumors
28 March, 2023
Egetis Therapeutics’ 2022 annual report published
22 February, 2023
Year-end Report Q4 2022
31 January, 2023
Change in the number of shares and votes in Egetis Therapeutics
27 January, 2023
Egetis recruits Katayoun Welin-Berger as Vice President Operations
25 January, 2023
Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 210 million
24 January, 2023
Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 200 million
2022
20 December, 2022
Egetis recruits Anny Bedard as President of Egetis North America
7 December, 2022
Egetis submits Expanded Access Program for Emcitate® in the USA
21 November, 2022
Egetis to participate at upcoming investor conferences
18 November, 2022
Egetis continues to strengthen the commercial and medical affairs organizations for the expected launch of Emcitate® in 2024
8 November, 2022
Interim report January-September 2022
Calendar and upcoming reports
November 8, 2023
Interim report January-September 2023
November 21-23, 2023
SEB Annual Healthcare Conference
